XDC Academy

Bispecific antibody-drug conjugates (BsADCs) represent a groundbreaking advancement in targeted therapy, combining the dual-targeting capabilities of bispecific antibodies with the potent payload delivery of antibody-drug conjugates (ADCs). By simultaneously targeting two distinct antigens or epitopes, BsADCs have the potential to overcome resistance mechanisms associated with single-target therapies, offering enhanced precision and therapeutic efficacy.

The field of BsADCs is rapidly expanding. As of February 15, 2025, nearly 200 BsADC candidates have been disclosed, spanning preclinical and clinical development stages, with five already advancing to Phase III trials.
 

This slide deck provides a comprehensive overview of BsADCs, including their mechanisms, competitive landscape, and WuXi XDC’s cutting-edge capabilities in BsADC development and other bioconjugate platforms. Explore how WuXi XDC is driving innovation in this transformative therapeutic space.